Protalix BioTherapeutics to Announce Q3 2025 Results on November 13, 2025, Hosts Conference Call and Webcast

Thursday, Nov 6, 2025 6:56 am ET1min read
PLX--

Protalix BioTherapeutics will announce its Q3 2025 financial and business results on November 13, 2025. The company will host a conference call and webcast at 8:00 a.m. EST to discuss the results and recent developments. Protalix is a biopharmaceutical company focused on developing recombinant therapeutic proteins through its ProCellEx plant cell-based expression system. Its licensed products include taliglucerase alfa for Gaucher disease and Elfabrio for Fabry disease. The company's development pipeline includes PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases.

Protalix BioTherapeutics to Announce Q3 2025 Results on November 13, 2025, Hosts Conference Call and Webcast

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet